## PROTHELIAL™ (POLYMERIZED CROSS-LINKED HIGH POTENCY SUCRALFATE): MEDICAL DEVICE THERAPY FOR TREATMENT AND PREVENTION OF MUCOSITIS

## Ricky W. McCullough MD MSc

Department of Medicine & Emergency Medicine Veterans Administration Medical Center, Teaching Hospital Warren Alpert Medical School of Brown University Providence, Rhode Island 02908 USA Department of Emergency Medicine Roger Williams Medical Center Providence, Rhode Island 02908 USA a Boston University School of Medicine Teaching Hospital

## **ABSTRACT**

Effective management of mucositis in cancer patients permits oncologists to optimize treatment regimens, achieve superior outcomes and maximize survival. To date there has been limited therapeutic options available to oncologists for effective mucositis management. ProThelial<sup>TM</sup> polymerized cross-linked high potency sucralfate recently cleared by the U.S. Food and Drug Administration as a hydrogel medical device for the management (treatment and prevention) of oral mucositis. In contradistinction to other mucositis interventions, ProThelial<sup>TM</sup> has been associated with 2-3 day rapid reversal of oral mucositis, complete prevention of oral mucositis and reversal of small bowel and colonic mucositis. It is likely to substantially impact the management of oral mucositis in patients undergoing treatment for cancer.

Keywords: Sucralfate, Mucositis, ProThelial, Chemo-radiation induced, Polymerized Sucralfate.